GLX Analytix is a startup at the intersection of health, biotechnology and medical technology, and fresh capital from EIFO, Labcorp Venture Fund ADDF is poised to nudge the company closer to commercialisation.
The Danish startup has developed a technology that can diagnose and monitor patients with neurodegenerative, autoimmune, and neuropsychiatric, neuropsychiatric and neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, and schizophrenia.
The technology combines artificial intelligence with biological markers from the blood vessels with the aim of improving, adapting and personalising treatment in the healthcare sector.
EIFO is among the investors who will help this important research reach the market. In recent years, Danish life science startups have attracted a lot of attention from both Danish and foreign investors:
"At EIFO, we work strategically with transformative technologies, and GLX Analytix is a great example of a promising innovation-driven and research-based company. They build on Denmark's positions of strength in diverse health technologies, combining both biotechnology and digital algorithms in a diagnostic solution. We are happy to help provide the venture capital that is so crucial to the commercialisation of vital research," says Christian Anker-Ladefoged.
GLX Analytix works with early diagnosis and monitoring of patients with neurodegenerative, autoimmune, and neuropsychiatric disorders. The company aims to revolutionise the treatment and monitoring of brain diseases.
Powerful new co-investors
EIFO has previously invested in GLX Analytix together with the US fund DigitalDx Ventures. In this round, EIFO and existing investors, together with Labcorp Venture Fund, the venture arm of one of the largest clinical laboratory operators in the world, and the Alzheimer's Drug Discovery Foundation (ADDF), a preeminent investor in transformative ideas to tackle Alzheimer’s Disease.
The fresh capital will accelerate GLX Analytix’s clinical validation efforts through strategic collaborations with hospitals in the USA, while also enhancing their commercial readiness with support from their newly formed Advisory Board.
“We are thrilled to have the strong support of our existing investors and have successfully attracted strategic investors like Labcorp and ADDF to join our company. GLX Analytix's mission to bring personalised medicine to millions of people worldwide is now closer to realisation with these strategic partnerships,” said Brian Della Valle, CEO and founder of GLX Analytix.
University spinout
GLX Analytix is a spinout from a collaboration between Aarhus University and Technical University of Denmark (DTU) where the foundations of the research were made. The name GLX Analytix comes from the glycocalyx (GLX), a seaweed-like structure on the blood vessel wall that is key to the research underpinning the technology. The GLX is an important part of the blood-brain barrier, specialised blood vessels in the brain. In conditions like multiple sclerosis, the GLX is degraded as an early sign of disease, opening the possibility that the technology can detect disease earlier from a blood sample, with a better chance to help.
The technology acts as a kind of fingerprint or signature that is intended to monitor and track the condition from a simple blood test, ensure the patient has the optimal treatment for them, and reducing side effects of treatment.
